35691950|t|Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy.
35691950|a|Amyotrophic lateral sclerosis (ALS) is an intractable disease that causes respiratory failure leading to mortality. The main locus of ALS is motor neurons. The success of antisense oligonucleotide (ASO) therapy in spinal muscular atrophy (SMA), a motor neuron disease, has triggered a paradigm shift in developing ALS therapies. The causative genes of ALS and disease-modifying genes, including those of sporadic ALS, have been identified one after another. Thus, the freedom of target choice for gene therapy has expanded by ASO strategy, leading to new avenues for therapeutic development. Tofersen for superoxide dismutase 1 (SOD1) was a pioneer in developing ASO for ALS. Improving protocols and devising early interventions for the disease are vital. In this review, we updated the knowledge of causative genes in ALS. We summarized the genetic mutations identified in familial ALS and their clinical features, focusing on SOD1, fused in sarcoma (FUS), and transacting response DNA-binding protein. The frequency of the C9ORF72 mutation is low in Japan, unlike in Europe and the United States, while SOD1 and FUS are more common, indicating that the target mutations for gene therapy vary by ethnicity. A genome-wide association study has revealed disease-modifying genes, which could be the novel target of gene therapy. The current status and prospects of gene therapy development were discussed, including ethical issues. Furthermore, we discussed the potential of axonal pathology as new therapeutic targets of ALS from the perspective of early intervention, including intra-axonal transcription factors, neuromuscular junction disconnection, dysregulated local translation, abnormal protein degradation, mitochondrial pathology, impaired axonal transport, aberrant cytoskeleton, and axon branching. We simultaneously discuss important pathological states of cell bodies: persistent stress granules, disrupted nucleocytoplasmic transport, and cryptic splicing. The development of gene therapy based on the elucidation of disease-modifying genes and early intervention in molecular pathology is expected to become an important therapeutic strategy in ALS.
35691950	12	41	amyotrophic lateral sclerosis	Disease	MESH:D000690
35691950	99	128	Amyotrophic lateral sclerosis	Disease	MESH:D000690
35691950	130	133	ALS	Disease	MESH:D000690
35691950	173	192	respiratory failure	Disease	MESH:D012131
35691950	233	236	ALS	Disease	MESH:D000690
35691950	270	295	antisense oligonucleotide	Chemical	MESH:D016376
35691950	297	300	ASO	Chemical	MESH:D016376
35691950	313	336	spinal muscular atrophy	Disease	MESH:D009134
35691950	338	341	SMA	Disease	MESH:D009134
35691950	346	366	motor neuron disease	Disease	MESH:D016472
35691950	413	416	ALS	Disease	MESH:D000690
35691950	451	454	ALS	Disease	MESH:D000690
35691950	512	515	ALS	Disease	MESH:D000690
35691950	625	628	ASO	Chemical	MESH:D016376
35691950	691	699	Tofersen	Species	
35691950	704	726	superoxide dismutase 1	Gene	6647
35691950	728	732	SOD1	Gene	6647
35691950	762	765	ASO	Chemical	MESH:D016376
35691950	770	773	ALS	Disease	MESH:D000690
35691950	918	921	ALS	Disease	MESH:D000690
35691950	982	985	ALS	Disease	MESH:D000690
35691950	1027	1031	SOD1	Gene	6647
35691950	1033	1049	fused in sarcoma	Gene	2521
35691950	1051	1054	FUS	Gene	2521
35691950	1124	1131	C9ORF72	Gene	203228
35691950	1204	1208	SOD1	Gene	6647
35691950	1213	1216	FUS	Gene	2521
35691950	1619	1622	ALS	Disease	MESH:D000690
35691950	1813	1836	mitochondrial pathology	Disease	MESH:D028361
35691950	2258	2261	ALS	Disease	MESH:D000690
35691950	Negative_Correlation	MESH:D016376	MESH:D016472
35691950	Negative_Correlation	MESH:D016376	6647
35691950	Association	MESH:D000690	2521
35691950	Negative_Correlation	MESH:D016376	MESH:D009134
35691950	Negative_Correlation	MESH:D016376	MESH:D000690
35691950	Association	MESH:D000690	6647

